On Wednesday, April 22, Galileo Analytics Co- Founder Anna McCollister-Slipp will join Congressman Fred Upton, Chairman of the House Committee on Energy and Commerce, as well as representatives from Pfizer, Novartis and Faster Cures at a Global Women Innovation Network (GlobalWIN) luncheon, to discuss the 21st Century Cures Initiative.

Spearheaded by Chairman Upton (R-MI) and Rep. Diana DeGette (D-CO), the bi-
partisan 21st Century Cures Initiative is aimed at developing legislation that will enable and accelerate the discovery, development and delivery of new treatments, while building our nation’s capacity to continue to serve as the global hub of biomedical innovation.

Congressman Upton will provide introductory remarks, followed by a panel discussion, which includes McCollister-Slipp, along with women leaders from pharma, the Hill and patient advocacy.

More information about the luncheon is below:

Global Women’s Innovation Network Luncheon on Innovation in Healthcare in the 21st Century

 

Introductory remarks by Congressman Fred Upton. Chairman, House Committee on Energy and Commerce

Followed by a panel discussion featuring:

  • Kirsten Axelsen
    Vice President of Worldwide Policy, Pfizer, Inc.
  • Cathryn M. Clary, MD
    Head of US Medical and Chief Scientific Officer for
    US General Medicines Novartis Pharmaceuticals Corporation
  • Anna McCollister-Slipp
    Co-Founder, Galileo Analytics
  • Margaret Anderson
    Executive Director, Faster Cures
  • Carly McWilliams (moderator)
    Professional Staff, Subcommittee on Health, US House of Representatives Committee on Energy and Commerce

 

Wednesday, April 22nd, 2015
12:00pm – 1:30pm

McDermott Will & Emery
The McDermott Building
500 North Capitol Street, NW
Washington, DC

Space is Limited. RSVP to Annele Jones at *protected email*

About the 21st Century Cures Initiative

In April 2014, Energy and Commerce Committee Chairman Fred Upton (R-MI) partnered with Rep. Diana DeGette (DCO) to launch the 21st Century Cures initiative. It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95 percent of [such] drugs fail during development.” Over the course of the last year, patients, providers, innovators, regulators, and researchers from around the country have provided a wide range of specific ideas on how Congress can help accelerate the discovery, development, and delivery of promising new treatments and cures for patients and maintain our nation’s standing as the biomedical innovation capital of the world. While it remains a work in progress, the legislative language included in the discussion document is based on such ideas, including proposals authored by both Republicans and Democrats.

About GlobalWIN

GlobalWIN is a 501(c)(3) organization co-chaired by Congresswoman Martha Roby and Congresswoman Debbie Wasserman Schultz that provides a dynamic forum for women executives and thought leaders in academia, government, and business who are passionate about innovation and its potential to advance critical policy issues.

Admin

About Admin

Anna McCollister-Slipp is co-founder of Galileo Analytics, a Visual Data Exploration and advanced data analytics company focused on democratizing access to and understanding of complex health data. In addition, she is the Chief Advocate for Participatory Research at the Scripps Translational Science Institute, where she is charged with bringing the expertise of patients, caregivers and community physicians into the design of health research. Anna’s passion for innovation in health data research is rooted in her personal experiences living with type 1 diabetes. As an entrepreneur and advocate, she speaks frequently about the promise of digital health, the imperative for patient data access and the need for improved outcomes measures for chronic disease. Anna serves on a number of government and private committees and boards aimed at promoting innovative ways to better understand, manage and treat complex health conditions, such as diabetes.

%d bloggers like this: